Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

18F-DOPA PET/CT in brain tumors: impact on multidisciplinary brain tumor board decisions.

Humbert O, Bourg V, Mondot L, Gal J, Bondiau PY, Fontaine D, Saada-Bouzid E, Paquet M, Chardin D, Almairac F, Vandenbos F, Darcourt J.

Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):558-568. doi: 10.1007/s00259-018-4240-8. Epub 2019 Jan 5.

PMID:
30612162
2.

Impact of 3,4-dihydroxy-6-18F-fluoro-L-phenylalanine PET/CT on managing patients with brain tumors: the referring physician's perspective.

Walter F, Cloughesy T, Walter MA, Lai A, Nghiemphu P, Wagle N, Fueger B, Satyamurthy N, Phelps ME, Czernin J.

J Nucl Med. 2012 Mar;53(3):393-8. doi: 10.2967/jnumed.111.095711. Epub 2012 Feb 9.

3.

123I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastoma.

Bleeker G, Tytgat GA, Adam JA, Caron HN, Kremer LC, Hooft L, van Dalen EC.

Cochrane Database Syst Rev. 2015 Sep 29;(9):CD009263. doi: 10.1002/14651858.CD009263.pub2. Review.

4.

Comparison of the amino acid tracers 18F-FET and 18F-DOPA in high-grade glioma patients.

Lapa C, Linsenmann T, Monoranu CM, Samnick S, Buck AK, Bluemel C, Czernin J, Kessler AF, Homola GA, Ernestus RI, Löhr M, Herrmann K.

J Nucl Med. 2014 Oct;55(10):1611-6. doi: 10.2967/jnumed.114.140608. Epub 2014 Aug 14.

5.

Value of 18F-3,4-dihydroxyphenylalanine PET/MR image fusion in pediatric supratentorial infiltrative astrocytomas: a prospective pilot study.

Morana G, Piccardo A, Milanaccio C, Puntoni M, Nozza P, Cama A, Zefiro D, Cabria M, Rossi A, Garrè ML.

J Nucl Med. 2014 May;55(5):718-23. doi: 10.2967/jnumed.113.125500. Epub 2014 Mar 20.

6.

Ability of (18)F-DOPA PET/CT and fused (18)F-DOPA PET/MRI to assess striatal involvement in paediatric glioma.

Morana G, Puntoni M, Garrè ML, Massollo M, Lopci E, Naseri M, Severino M, Tortora D, Rossi A, Piccardo A.

Eur J Nucl Med Mol Imaging. 2016 Aug;43(9):1664-72. doi: 10.1007/s00259-016-3333-5. Epub 2016 Feb 25.

PMID:
26911489
7.

Accuracy of F-DOPA PET and perfusion-MRI for differentiating radionecrotic from progressive brain metastases after radiosurgery.

Cicone F, Minniti G, Romano A, Papa A, Scaringi C, Tavanti F, Bozzao A, Maurizi Enrici R, Scopinaro F.

Eur J Nucl Med Mol Imaging. 2015 Jan;42(1):103-11. doi: 10.1007/s00259-014-2886-4. Epub 2014 Aug 15.

PMID:
25182751
8.

Comparison of 18F-dopa PET/CT and 123I-MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study.

Piccardo A, Lopci E, Conte M, Garaventa A, Foppiani L, Altrinetti V, Nanni C, Bianchi P, Cistaro A, Sorrentino S, Cabria M, Pession A, Puntoni M, Villavecchia G, Fanti S.

Eur J Nucl Med Mol Imaging. 2012 Jan;39(1):57-71. doi: 10.1007/s00259-011-1938-2. Epub 2011 Sep 20.

PMID:
21932116
9.

Intra-individual comparison of ¹⁸F-FET and ¹⁸F-DOPA in PET imaging of recurrent brain tumors.

Kratochwil C, Combs SE, Leotta K, Afshar-Oromieh A, Rieken S, Debus J, Haberkorn U, Giesel FL.

Neuro Oncol. 2014 Mar;16(3):434-40. doi: 10.1093/neuonc/not199. Epub 2013 Dec 4.

10.

Complementary roles of 18F-DOPA PET/CT and 18F-FDG PET/CT in medullary thyroid cancer.

Kauhanen S, Schalin-Jäntti C, Seppänen M, Kajander S, Virtanen S, Schildt J, Lisinen I, Ahonen A, Heiskanen I, Väisänen M, Arola J, Korsoff P, Ebeling T, Sane T, Minn H, Välimäki MJ, Nuutila P.

J Nucl Med. 2011 Dec;52(12):1855-63. doi: 10.2967/jnumed.111.094771. Epub 2011 Nov 3.

11.

The role of ¹⁸F-FDG PET/CT in the assessment of suspected recurrent gastric cancer after initial surgical resection: can the results of FDG PET/CT influence patients' treatment decision making?

Bilici A, Ustaalioglu BB, Seker M, Kefeli U, Canpolat N, Tekinsoy B, Ozugur S, Gumus M.

Eur J Nucl Med Mol Imaging. 2011 Jan;38(1):64-73. doi: 10.1007/s00259-010-1611-1. Epub 2010 Sep 14.

PMID:
20838995
12.

Current status of 18F-DOPA PET imaging in the detection of brain tumor recurrence.

Calabria F, Cascini GL.

Hell J Nucl Med. 2015 May-Aug;18(2):152-6. doi: 10.1967/s0024499100211. Epub 2015 Jul 20. Review.

13.

(18)F-DOPA PET/CT in the diagnosis and localization of persistent medullary thyroid carcinoma.

Archier A, Heimburger C, Guerin C, Morange I, Palazzo FF, Henry JF, Schneegans O, Mundler O, Abdullah AE, Sebag F, Imperiale A, Taïeb D.

Eur J Nucl Med Mol Imaging. 2016 Jun;43(6):1027-33. doi: 10.1007/s00259-015-3227-y. Epub 2015 Oct 24.

PMID:
26497699
14.

Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study.

Koopmans KP, de Vries EG, Kema IP, Elsinga PH, Neels OC, Sluiter WJ, van der Horst-Schrivers AN, Jager PL.

Lancet Oncol. 2006 Sep;7(9):728-34.

PMID:
16945767
15.

Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma.

Beuthien-Baumann B, Strumpf A, Zessin J, Bredow J, Kotzerke J.

Eur J Nucl Med Mol Imaging. 2007 Oct;34(10):1604-9. Epub 2007 Apr 14.

PMID:
17435996
16.

Diagnostic utility of PET/CT with 18F-DOPA and 18F-FDG in persistent or recurrent medullary thyroid carcinoma: the importance of calcitonin and carcinoembryonic antigen cutoff.

Romero-Lluch AR, Cuenca-Cuenca JI, Guerrero-Vázquez R, Martínez-Ortega AJ, Tirado-Hospital JL, Borrego-Dorado I, Navarro-González E.

Eur J Nucl Med Mol Imaging. 2017 Nov;44(12):2004-2013. doi: 10.1007/s00259-017-3759-4. Epub 2017 Jun 23.

PMID:
28646462
17.

Grading and outcome prediction of pediatric diffuse astrocytic tumors with diffusion and arterial spin labeling perfusion MRI in comparison with 18F-DOPA PET.

Morana G, Piccardo A, Tortora D, Puntoni M, Severino M, Nozza P, Ravegnani M, Consales A, Mascelli S, Raso A, Cabria M, Verrico A, Milanaccio C, Rossi A.

Eur J Nucl Med Mol Imaging. 2017 Nov;44(12):2084-2093. doi: 10.1007/s00259-017-3777-2. Epub 2017 Jul 27.

PMID:
28752225
18.

18F-DOPA PET/CT in the evaluation of hereditary SDH-deficiency paraganglioma-pheochromocytoma syndromes.

Marzola MC, Chondrogiannis S, Grassetto G, Rampin L, Maffione AM, Ferretti A, Opocher G, Schiavi F, Colletti PM, Rubello D.

Clin Nucl Med. 2014 Jan;39(1):e53-8. doi: 10.1097/RLU.0b013e31829aface.

PMID:
23856824
19.

Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours.

Haug A, Auernhammer CJ, Wängler B, Tiling R, Schmidt G, Göke B, Bartenstein P, Pöpperl G.

Eur J Nucl Med Mol Imaging. 2009 May;36(5):765-70. doi: 10.1007/s00259-008-1030-8. Epub 2009 Jan 10.

PMID:
19137293
20.

Predictive and prognostic value of 18F-DOPA PET/CT in patients affected by recurrent medullary carcinoma of the thyroid.

Caobelli F, Chiaravalloti A, Evangelista L, Saladini G, Schillaci O, Vadrucci M, Scalorbi F, Donner D, Alongi P; Young AIMN Working Group.

Ann Nucl Med. 2018 Jan;32(1):7-15. doi: 10.1007/s12149-017-1213-0. Epub 2017 Oct 6. Erratum in: Ann Nucl Med. 2018 Jul;32(6):430.

PMID:
28986764

Supplemental Content

Support Center